Clinical trials in neonates: a therapeutic imperative

Area of Science:

• Pharmacology
• Pediatric Medicine
• Drug Development

Background:

• Children have historically been excluded from clinical drug trials, leading to a lack of evidence-based prescribing information.
• The term "therapeutic orphans" highlights the critical gap in pediatric medication research since the 1960s.
• Early drug labeling in 1968 showed inadequate pediatric information for only 25% of approved medications.

Purpose of the Study:

• To examine the historical evolution of pediatric drug research and labeling.
• To assess the impact of legislative changes on the inclusion of pediatric data in drug approvals.
• To identify remaining gaps in pediatric prescribing information, particularly for neonatal populations.

Main Methods:

• Historical analysis of drug approval data and labeling changes.
• Review of key legislation aimed at improving pediatric drug research, including the FDA Modernization Act (1997), Best Pharmaceuticals for Children Acts, and Pediatric Research Equity Acts.
• Comparative analysis of pediatric prescribing information availability over time.

Main Results:

• Significant improvements in pediatric prescribing information occurred following legislative efforts starting in the 1990s.
• By 2009, over 300 labeling changes enhanced pediatric drug information.
• Despite progress, comprehensive data and labeling for neonatal populations remained notably insufficient.

Conclusions:

• Legislative actions have demonstrably improved pediatric drug information over the past decades.
• Continued focus is needed to ensure adequate research and labeling for all pediatric age groups, especially newborns.
• Addressing the "therapeutic orphan" issue requires ongoing commitment to pediatric pharmacology research.